Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms

Centro de Estudios de Mastocitosis de Castilla La Mancha, Hospital Virgen del Valle, Toledo, Spain.
The Journal of allergy and clinical immunology (Impact Factor: 11.48). 06/2010; 125(6):1269-1278.e2. DOI: 10.1016/j.jaci.2010.02.019
Source: PubMed


Systemic mast cell activation disorders (MCADs) are characterized by severe and systemic mast cell (MC) mediators-related symptoms frequently associated with increased serum baseline tryptase (sBt).
To analyze the clinical, biological, and molecular characteristics of adult patients presenting with systemic MC activation symptoms/anaphylaxis in the absence of skin mastocytosis who showed clonal (c) versus nonclonal (nc) MCs and to provide indication criteria for bone marrow (BM) studies.
Eighty-three patients were studied. Patients showing clonal BM MCs were grouped into indolent systemic mastocytosis without skin lesions (ISMs(-); n = 48) and other c-MCADs (n = 3)-both with CD25(++) BM MCs and either positive mast/stem cell growth factor receptor gene (KIT) mutation or clonal human androgen receptor assay (HUMARA) tests-and nc-MCAD (CD25-negative BM MCs in the absence of KIT mutation; n = 32) and compared for their clinical, biological, and molecular characteristics.
Most clonal patients (48/51; 94%) met the World Health Organization criteria for systemic mastocytosis and were classified as ISMs(-), whereas the other 3 c-MCAD and all nc-MCAD patients did not. In addition, although both patients with ISMs(-) and patients with nc-MCAD presented with idiopathic and allergen-induced anaphylaxis, the former showed a higher frequency of men, cardiovascular symptoms, and insect bite as a trigger, together with greater sBt. Based on a multivariate analysis, a highly efficient model to predict clonality before BM sampling was built that includes male sex (P = .01), presyncopal and/or syncopal episodes (P = .009) in the absence of urticaria and angioedema (P = .003), and sBt >25 microg/L (P = .006) as independent predictive factors.
Patients with c-MCAD and ISMs(-) display unique clinical and laboratory features different from nc-MCAD patients. A significant percentage of c-MCAD patients can be considered as true ISMs(-) diagnosed at early phases of the disease.

1 Follower
8 Reads
    • "The diagnosis of mastocytosis requires a multidisciplinary work-up with the involvement of different groups of medical experts. This is due to the fact that, despite that the majority of patients present with dermatological symptoms, in a substantial fraction of the cases the disease emerges as a MC activation syndrome or a malignant haematological disorder, frequently in the absence of skin lesions (Bonadonna et al, 2009; Alvarez-Twose et al, 2010, 2012; Valent et al, 2011; Matito et al, 2014). Moreover, the last decade has seen a great improvement in the diagnosis of SM due to the development and use of an increasingly broad panel of more sensitive and specific techniques to assess BM involvement [e.g. by flow cytometry immunophenotyping and polymerase chain reaction (PCR)-based molecular assays] (Valent et al, 2007; Horny et al, 2008; Teodosio et al, 2010; Sanchez- Munoz et al, 2011a), in addition to the more conventional assays. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis of 'rare diseases', such as mastocytosis, remains a challenge. Despite this, the precise benefits of referral of mastocytosis patients to highly specialized reference centres are poorly defined and whether patients should be managed at non-specialized versus reference centres remains a matter of debate. To evaluate the quality and efficiency of diagnostic procedures performed at the reference centres for mastocytosis in Spain (REMA) versus other non-reference centres, we retrospectively analysed a series of 122 patients, for the overall degree of agreement obtained for the World Health Organization (WHO) diagnostic and classification criteria betwen the referring and REMA centres. Our results showed that not all WHO diagnostic criteria were frequently investigated at the referring centres. Among the five WHO diagnostic criteria, the highest degree of agreement was obtained for serum tryptase levels [median 90% (95% confidence interval 84-96%)]; in turn, the overall agreement was significantly lower for the major histopathological criterion [80% (72-89%)], and the other three minor criteria: cytomorphology [68% (56-80%)] immunophenotyping of BM mast cells [75% (62-87%)] and detection of the KIT mutation [34% (8-60%)]. Referral of patients with diagnostic suspicion of mastocytosis to a multidisciplinary reference centre improves diagnostic efficiency and quality.
    British Journal of Haematology 10/2015; DOI:10.1111/bjh.13789 · 4.71 Impact Factor
  • Source
    • "individuals with a history of drug-induced anaphylaxis. The incriminated drugs in this study were β-lactam antibiotics (4x), fosfomycin, NSAID (4x), codeine, mepivacaine, and rocuronium and in 4 patients hypersensitivity reactions could not be attributed to a single identifiable drug [21]. In our cohort of 284 NSAID hypersensitive patients we identified 26 who showed basal serum tryptase levels of > 10 ng/mL. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is hypothesized that because of higher mast cell numbers and mediator release, mastocytosis predisposes patients for systemic immediate-type hypersensitivity reactions to certain drugs including non-steroidal anti-inflammatory drugs (NSAID). To clarify whether patients with NSAID hypersensitivity show increased basal serum tryptase levels as sign for underlying mast cell disease. As part of our allergy work-up, basal serum tryptase levels were determined in all patients with a diagnosis of NSAID hypersensitivity and the severity of the reaction was graded. Patients with confirmed IgE-mediated hymenoptera venom allergy served as a comparison group. Out of 284 patients with NSAID hypersensitivity, 26 were identified with basal serum tryptase > 10.0 ng/mL (9.2%). In contrast, significantly (P = .004) more hymenoptera venom allergic patients had elevated tryptase > 10.0 ng/mL (83 out of 484; 17.1%). Basal tryptase > 20.0 ng/mL was indicative for severe anaphylaxis only in venom allergic subjects (29 patients; 4x grade 2 and 25x grade 3 anaphylaxis), but not in NSAID hypersensitive patients (6 patients; 4x grade 1, 2x grade 2). In contrast to hymenoptera venom allergy, NSAID hypersensitivity do not seem to be associated with elevated basal serum tryptase levels and levels > 20 ng/mL were not related to increased severity of the clinical reaction. This suggests that mastocytosis patients may be treated with NSAID without special precautions.
    Allergy Asthma and Clinical Immunology 04/2014; 10(1):19. DOI:10.1186/1710-1492-10-19 · 2.03 Impact Factor
  • Source
    • "However, this practice has not yet come under consideration as a standard routine. Interestingly, the Spanish Network on Mastocytosis has recently proposed a scoring method to prescreen HVA patients before a possible further investigation with bone marrow examination in order to determine underlying CMD [23]. All three cases in our study scored enough to qualify bone marrow examination supporting that REMA-score could be beneficial tool in similar cases. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hymenoptera venom allergy (HVA) represents a particular risk for exceptionally severe anaphylactic sting reactions in patients with clonal mast cell disorders (CMD). Nevertheless, conventional investigations are not sufficient to do accurate risk assessments. Increased levels of baseline serum tryptase (sBT) (>11.4 μg/L) is highly associated with severe anaphylactic reactions and with a possible underlying CMD. The measurement of baseline serum tryptase, thus, has opened the possibility to screen for CMD. In the present study, we sought to investigate whether bone marrow evaluation provides more accurate diagnosis in patients with HVA. Three patients of the same sex and similar age with HVA were enrolled in this clinical study. The patients underwent comprehensive allergy work-up including skin prick testing, measurements of serum total IgE concentrations and baseline serum tryptase. Bone-marrow biopsies were also performed in all three patients to assess underlying CMD. We evaluated characteristics of the bone marrow mast cells by pathology, flow cytometry and detection of D816V mutation by using current WHO-criteria, which led to changes in the final diagnosis compared to the assessments done by classical allergy work-up and measurements of sBT. Three distinct diagnostic outcomes including systemic mastocytosis, monoclonal mast cell activation syndrome and non-clonal HVA were revealed. We conclude that a bone marrow investigation is required for the correct diagnosis of hymenoptera venom-induced anaphylactic reactions in patients with elevated baseline tryptase levels (>11.4 μg/L), and this has important implications for management strategies.
    07/2013; 3(1):22. DOI:10.1186/2045-7022-3-22
Show more

Similar Publications